The findings from a new survey suggest that lack of direct communication between clinicians and patients, as well as false beliefs about STD risk held by both groups, may contribute to STD prevalence.
The survey examined the perceptions of 3,414 young women (15-24 years of age), 1,016 mothers of young women in this age group, and 312 primary care, OB/GYN, and other specialty physicians regarding sexual activity, sexual health, and knowledge of and screening for STDs, also known as sexually transmitted infections (STIs).
Key findings from the survey reveal that young women may not understand their STD risk. Young sexually active women cite "not feeling at risk" and "being asymptomatic" as reasons for not testing, although STDs often lack symptoms.
Fifty-one percent of young women are uncomfortable talking to their clinician about sex and STDs, and 27% may fail to be truthful with their clinician about their sexual history. For the youngest sexually active women (15-17 years of age), 43% aren't always truthful.
Additionally, 49% of young women don't recall having a clinician ask about STD screening, and less than one in four sexually active women has asked their healthcare professional for an STD test. Based on the comparison of responses of sexually active women 15-17 between 2015 and 2017, STD testing by clinicians for chlamydia and gonorrhea has decreased by 9% and 11%, respectively.
The survey also found gaps in care by some physicians, with one in four primary care physicians agreeing with the statement, "I am very uncomfortable discussing STI risk with my female patients," and 27% reporting that they could accurately diagnose STD patients "based on their symptoms," even though CDC notes, "STDs do not always cause symptoms, so it is possible to have an infection and not know it."
Additionally, one in four physicians will disregard screening guidelines if a patient is asymptomatic.
Quest provides diagnostic services to one in three American adults each year, with broad national access for patients through its 2,200 patient service centers, and relationship with half of all physicians and hospitals.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study